Trade Aldeyra Therapeutics, Inc. - ALDX CFD

Trading Conditions

• Spread: 0.05
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 3.91
• Open: 3.88
• 1-Year Change: -56.98%
• Day's Range: 3.81 - 3.93

Aldeyra Therapeutics, Inc. Company profile

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 54% to $57.8M. Higher net loss reflects Research and development increase of 98% to $41.4M (expense), General and administrative increase of 15% to $7.7M (expense), General and administrative expenses increase of 8% to $3.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.07.